These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30337961)

  • 1. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
    Zhang H; Chen D
    Thyroid Res; 2018; 11():13. PubMed ID: 30337961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and
    Anekpuritanang T; Uataya M; Claimon A; Laokulrath N; Pongsapich W; Pithuksurachai P
    Onco Targets Ther; 2021; 14():3959-3969. PubMed ID: 34234465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 6. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
    Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring
    Fu H; Cheng L; Jin Y; Cheng L; Liu M; Chen L
    Mol Ther Oncolytics; 2019 Mar; 12():235-245. PubMed ID: 30847387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
    Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
    Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner.
    Vadysirisack DD; Venkateswaran A; Zhang Z; Jhiang SM
    Endocr Relat Cancer; 2007 Jun; 14(2):421-32. PubMed ID: 17639055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.
    Jia Y; Zhang C; Hu C; Yu Y; Zheng X; Li Y; Gao M
    Oncol Lett; 2018 May; 15(5):6763-6769. PubMed ID: 29616135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
    Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
    Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.